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Articles
Dynamic ElecTronic hEalth reCord deTection (DETECT) 
of individuals at risk of a first episode of psychosis: 
a case-control development and validation study
Lars Lau Raket*, Jörn Jaskolowski*, Bruce J Kinon, Jens Christian Brasen, Linus Jönsson, Allan Wehnert, Paolo Fusar-Poli
Summary
Background Many individuals who will experience a first episode of psychosis (FEP) are not detected before occurrence, 
limiting the effect of preventive interventions. The combination of machine-learning methods and electronic health 
records (EHRs) could help address this gap.
Methods This case-control development and validation study is based on EHR data from IBM Explorys. The IBM 
Explorys Platform holds standardised, longitudinal, de-identified, patient-level EHR data pooled from different 
health-care systems with distinct EHRs. The present EHR-based studies were retrospective, matched (1:1), case-
control studies compliant with RECORD, STROBE, and TRIPOD statements. The study included individuals in the 
IBM Explorys database who at some point between 1990 and 2018 had a diagnosis of FEP followed by schizophrenia, 
and psychosis-free matched control individuals from a random subsample of the full cohort. For every individual in 
the FEP cohort, the individual in the control cohort was matched to have a similar date for inclusion in the database 
and a similar total observation time. Individuals in the FEP cohort had their index date defined as the first diagnosis 
of psychosis or the first prescription of antipsychotic medication. Individuals in the control cohort had their index 
date defined to occur the same number of days after inclusion in the database as their matching FEP individual. The 
FEP and control cohorts were both randomly split into development and validation datasets in a ratio of 7:3. The 
subset of individuals in the validation dataset who had all their health-care encounters at providers that were not seen 
in the development dataset made up the external validation subset. A novel recurrent neural network model was 
developed to predict the risk of FEP 1 year before the index date by employing demographics and medical events (in 
the categories diagnoses, prescriptions, procedures, encounters and admissions, observations, and laboratory test 
results) dynamically collected in the EHR as part of clinical routine. We named the recurrent neural network Dynamic 
ElecTronic hEalth reCord deTection (DETECT). The main outcomes were accuracy and area under receiver operating 
characteristic curve (AUROC). Decision-curve analyses and dynamic patient journey plots were used to evaluate 
clinical usefulness. 
Findings The FEP and control cohorts each comprised 72 860 individuals. 102 030 individuals (51 015 matching pairs) 
were randomly allocated to the development dataset and the remaining 43 690 to the validation dataset. In the 
validation dataset, 4770 individuals had all their encounters outside of the 118 790 health-care providers that were 
encountered in the development dataset. The data from these individuals made up the external validation subset. The 
median follow-up (observation time before index date) was 6·0 years (IQR 3·0–10·4). In the development dataset, 
DETECT’s prognostic accuracy was 0·787 and AUROC was 0·868. In the validation dataset, DETECT’s prognostic 
accuracy was 0·774 and AUROC was 0·856. In the external test subset, DETECT’s balanced prognostic accuracy was 
0·724 and AUROC was 0·799. Prevalence-adjusted decision-curve analyses suggested that DETECT was associated 
with a positive net benefit in two different scenarios for FEP detection.
Interpretation DETECT showed adequate prognostic accuracy to detect individuals at risk of developing a FEP in 
primary and secondary care. Replication and refinement in a population-based setting are needed to consolidate these 
findings.
Funding Lundbeck.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Schizophrenia is a disabling psychiatric disorder, 
diagnosed in more than 21 million people around the 
world, with high social and economic costs for patients, 
their families, and society.1–4 In patients with schizophrenia, 
the first episode of psychosis (FEP) is a key event that 
defines long-term outcomes.5 Although antipsychotic 
treatments are effective,6,7 once the first episode of 
psychosis occurs there are only limited possibilities to 
improve long-term outcomes.8,9 Prevention or delay of 
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disease progression would therefore have a great impact 
on a personal and societal level.5,9,10 However, the first 
rate-limiting step towards successful prevention of 
schizophrenia and other psychotic disorders is the 
detection of at-risk individuals before they experience 
psychotic episodes.11 Currently, only 5–12% of individuals 
who will experience a first episode of psychosis are detected 
during their at-risk stage, before the disorder occurs.12,13 
Individuals at risk for psychosis are identified on the basis 
of a prototypical presentation of subtle symptoms that 
meet a clinical high-risk state for psychosis (CHR-P).14–16 
Identification of these symptoms is based on functional 
impairment17 and help-seeking behaviours,18 and depends 
on the ability of clinicians or caregivers to recognise these 
features and initiate a referral to specialised clinics.19 
Therefore, the detection of individuals at risk for psychosis 
is hampered by complex pathways to care and unsystematic 
approaches that lead to substantial sampling bias.19,20 An 
additional limitation is that about one-third of patients 
with a FEP might not experience a CHR-P stage before the 
onset of their illness.21,22 Finally, it is not currently possible 
to predict the risk of developing a FEP at the individual 
patient level.
One possible way of overcoming the challenges to detect 
individuals at risk for psychosis  earlier might be to 
leverage electronic health records (EHRs), which are 
increasingly adopted across primary and secondary health-
care systems.19 EHRs represent real-word clinical 
information and as such they are ideally positioned to 
improve the detection of individuals at risk of psychosis on 
a large scale.11 Furthermore, EHRs can contain large 
amounts of patient information in addition to symptom 
presentation, and thus offer a unique opportunity to drive 
the multimodal prediction of outcomes at the individual 
patient level. Finally, information contained in EHRs can 
be used to transdiagnostically detect individuals at risk of 
psychosis beyond the CHR-P paradigm.23 Two studies 
using EHRs have confirmed that EHRs in secondary 
mental health care could improve the detection of 
individuals at risk of psychosis.12,24 Our study expands this 
line of research by using the IBM Explorys database (one 
of the largest available real-world EHR databases that 
includes primary care and secondary care data) in combi-
nation with state-of-the-art machine-learning methods: the 
combination of these approaches has previously proven to 
be valuable in risk predictions of various diseases.25–29 Our 
main hypothesis was that the combination of EHR and 
machine-learning methods would enable an above-chance 
prognostic accuracy for the personalised detection of 
individuals at risk of developing a FEP.
Methods
Study design and participants
This case-control development and validation study is 
based on EHR data from IBM Explorys. The IBM Explorys 
Platform holds longitudinal patient-level EHR data pooled 
from different health-care systems with distinct EHRs. 
Data were standardised and normalised using common 
ontologies (appendix p 2), searchable through a Health 
Insurance Portability and Accountability Act (HIPAA)-
enabled, de-identified dataset from IBM Explorys. 
Individuals were seen in multiple primary and secondary 
health-care systems from 1990 to 2018 with a combination 
of data from clinical electronic medical records, health-
care system outgoing bills, and adjudicated payer claims. 
The data span the continuum of health care and were 
collected and linked from over 920 000 providers, covering 
approximately 15% of the US population at the time of this 
study.30 The database contains billions of patient-level 
entries in the categories of demographics, diagnoses, drug 
See Online for appendix
Research in context
Evidence before this study
We established the current state of risk prediction using electronic 
health records (EHRs) in general, and specifically for first episode 
of psychosis (FEP), including schizophrenia, by searching PubMed 
and Google Scholar for studies published in English up to 
Aug 19, 2019, using the keywords “electronic health record(s)”, 
“prediction”, “psychosis”, and “schizophrenia”. We found many 
recent studies that successfully applied machine-learning 
methods to risk prediction on EHRs, but only a few studies 
predicted FEP or schizophrenia. In these, the case numbers were 
typically low and generalisability was therefore unclear.
Added value of this study
We developed and validated Dynamic ElecTronic hEalth reCord 
deTection (DETECT): the first individualised risk-prediction 
model that leverages large-scale screening of EHRs to detect 
individuals at risk of FEP. DETECT was based on a recurrent 
neural network model, and predicted whether a FEP (which 
developed into schizophrenia) would occur 1 year before its 
onset with an area under receiver operating characteristic curve 
of 0·856. Prevalence-adjusted decision-curve analyses found 
that detection based on DETECT was associated with a positive 
net benefit for cost-benefit ratios as low as 1:16, suggesting 
potential clinical utility of the model.
Implications of all the available evidence
Early detection of most individuals at risk of psychotic disorders 
can improve their long-term outcomes. Successful application of 
machine-learning methods to detect individuals at increased risk 
on the basis of existing data is a low-cost approach to increase 
value of EHR data, with the potential to benefit patients and 
society. The results of our study suggest that using DETECT for 
large-scale screening is associated with potential clinical benefits. 
Future studies are needed to confirm and refine these findings in 
a population-based setting, and to investigate if the results can 
be replicated in other countries. Finally, there is a need to 
investigate whether EHR-based risk-prediction models like 
DETECT can be fully implemented in real-world clinical practice.
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prescriptions, procedures, encounters and admissions, 
observations (eg, blood pressure or body-mass index), and 
laboratory test results.30 Further information on data 
representation and processing is available in the 
appendix (pp 2–3). The aggregated data that Explorys 
assembles from different health-care providers has been 
statistically de-identified to meet the requirements of 
45 Code of Federal Regulations §  164.514(b). All data used 
from Explorys were de-identified to meet 1996 HIPAA and 
2009 Health Information Technology for Economic and 
Clinical Health (HITECH) standards. Business affiliation 
agree ments were in place between all participating health-
care systems and Explorys regarding contribution of 
EHR data to the Explorys Platform and the use of these 
de-identified data. Patients who  indicated at patient 
onboarding that they did not wish to have their data used 
for de-identified secondary use were not included in the 
dataset.
From the Explorys database, we identified individuals 
with a diagnosis of International Classification of Diseases 
(ICD)-9 or ICD-10 schizophrenia. For all these individuals, 
the outcome of interest was the index date of their 
schizophrenic disorder. The index date was operationalised 
as the date of their first diagnosis of ICD-9 or ICD-10 
psychosis (including but not limited to schizophrenia, 
because the first diagnosis is often of a non-specific 
psychotic disorder) or the date of their first prescription of 
antipsychotic medication (figure 1). If the index date was 
defined by prescription of antipsychotic medication, the 
patient was excluded if the prescription was not followed 
by a diagnosis of ICD-9 or ICD-10 psychosis (including 
schizophrenia) within 5 years. Individuals were excluded if 
they had less than 1 year of data before the index date (see 
appendix p 2 for further exclusion criteria, psychosis ICD-9 
and ICD-10 codes, and antipsychotic medications). 
Individuals included in our study with a FEP who later 
developed schizophrenia were defined as the FEP cohort.
A control cohort without psychotic diagnoses or 
antipsychotic prescriptions was also defined. For every 
patient in the FEP cohort, a random psychosis-free control 
patient was selected, ensuring that the matched control 
patient had a similar date for inclusion in the database 
and was observed for a similar duration (days between 
first and last data entry). The rationale for matching on 
these variables and the matching algorithm are described 
in the appendix (p 3). For the matched control individuals, 
a pseudo-index date was defined to occur the same 
number of days after inclusion in the database as the 
corresponding patient with a FEP. Importantly, the control 
individuals were not matched on other variables such as 
age or sex, since the risk-prediction model should be able 
to modify its predictions on the basis of differences in age 
and sex. Furthermore, such matching on demographic 
variables would hamper generalisability to the whole 
population.
The FEP and control cohorts included patient data 
from the years 1990–2018, and to be eligible for either of 
the cohorts a patient had to be between 5–70 years of age 
on the index date and have a valid record of sex.
In the general population, occurrence of a FEP is a rare 
event with an overall incidence of 26·6 per 100 000 person-
years.31 Because of the computational complexity of 
handling extremely large datasets and training of deep-
learning models, a case-control design was chosen since 
Figure 1: Patient timeline and definition of index date for patients in the first episode of psychosis cohort
Demographics, diagnoses, prescriptions, 
procedures, encounters and admissions, 
observations, and laboratory test results
First data in 
electronic 
health record DETECT 
prediction




first diagnosis of 
any psychosis)
Any psychosis diagnosis 
allowed (required within 
5 years of index date if it 






Data cutoff Variable time
Figure 2: Flowchart of the study population
ICD= International Classification of Diseases. FEP=first episode of psychosis.*For 15 matching pairs both FEP and control 
patients have a diagnosis indicating psychosis before the index date.
IBM Explorys database 
189 054 patients with an ICD-9 
or ICD-10 schizophrenia 
diagnosis 
113 450 excluded (less than 1 year 
of data before first episode 
of psychosis, not between 
5–70 years of age at index 
date, evidence of psychotic 
illness before index date in 
medical history, no record 
of gender)
5488 individuals* (2744 matched 
pairs) excluded because one 
or both individuals had 
descriptions of diagnoses 
indicating psychosis before 
index date 
2510 patients with FEP
249 controls
10% random sample of 6·1 million 
individuals
75 604 eligible patients with FEP
 
75 604 eligible control patients 
with matching criteria
102 030 development (training) 
dataset 
51 015 patients with FEP
51 015 controls
 
43 690 validation (test) dataset
21 845 patients with FEP
21 845 controls






e232 www.thelancet.com/digital-health   Vol 2   May 2020
it allowed efficient utilisation of the information for all 
cases in the dataset, without the computational overhead 
of having to train the model on the full cohort that is 
several orders of magnitude larger than the case group. 
Given the large size of both case and control cohorts and 
the relatively weak matching criteria, it was hypothesised 
that the 1:1 matched control cohort would be sufficiently 
representative and contain enough variety of observed 
patterns of medical events to allow generalisation of the 
findings to the full cohort.
Outcomes
The outcome of interest (an ICD-9 or ICD-10 FEP which 
will be associated with schizophrenia), predictors, and 
time to index date were automatically extracted using 
IBM Explorys. The recurrent neural network model 
would forecast the likelihood of developing a FEP 1 year 
before occurrence. Predictors were based on availability 
with no a priori selection, encompassing events that are 
dynamically collected from the first data entry in the EHR 
to the cutoff date 1 year before the index date (figure 1). 
Only events observed in more than 50 individuals in the 
development (training) dataset were included in the 
analyses.
Exploratory analyses of the predictions made by the 
recurrent neural network model were done to identify 
the events that had the largest effect on the predictions. 
Dynamic patient journey plots were generated to allow 
exploration of the events driving the predictions on a 
patient level.
Statistical analysis
This clinical register-based study is reported according to 
the RECORD and STROBE statements.32 Model develop-
ment and validation followed methodological guidelines33 
that have been adapted to prognostic modelling in 
psychiatry34 and the TRIPOD statement.35 For descriptive 
purposes, the demographic characteristics of individuals 
in the FEP and control cohorts were compared, and 
potential differences tested at a 0·05 significance level 
using χ² tests for categorical variables and Wilcoxon tests 
for continuous variables. The geographical distributions 
of individuals in the FEP and control cohorts were also 
compared, and state-wise differences were tested using 
binomial tests with a Bonferroni-corrected significance 
cutoff of 0·001.
FEP and control cohorts were both randomly split into 
development (training) and validation (test) datasets in a 
ratio of 7:3, respecting the pair matching (FEP-control 
pairs had a similar date of inclusion and follow-up time). 
To further validate our risk-prediction model on health-
care providers that were external to the providers seen in 
the development dataset, unique identifiers of all health-
care providers that were encountered in the development 
dataset were extracted, and an external test subset was 
defined as the subset of the validation dataset with data 
from patients who only had health-care encounters 
outside of the providers seen in the development dataset.
Model development and validation
The development dataset was used for model development 
and optimisation of parameters. The recurrent neural 
network model, called Dynamic ElecTronic hEalth reCord 
deTection (DETECT), was built in Keras using Python 
(version 3.6.7). Other analyses were done using R (version 
3.3.1).36 Briefly, the recurrent neural network model 
learned an embedding of medical events that mapped 
medical events into a geometric representation relevant 
for the prediction task25 and represented an internal 
memory state of past events for a given patient using the 
gated recurrent unit architecture.37 The model was trained 
to find temporal patterns of events that could separate 
patients in the FEP and control cohorts using data of 






Female 41 286 (56·7%) 31 653 (43·4%)
Male 31 574 (43·3%) 41 207 (56·6%)
Birth year† 1969 (1956–86) 1965 (1956–79)
Age at index, years† 42 (25–55) 45 (32–55)
Race*
African American 10 347 (14·2%) 26 033 (35·7%)
Asian 1207 (1·7%) 792 (1·1%)
White 50 482 (69·3%) 38 777 (53·2%)
Hispanic or Latino 585 (0·8%) 330 (0·5%)
Multiracial 398 (0·5%) 289 (0·4%)
Other 1850 (2·5%) 1474 (2·0%)
Unknown 7991 (11·0%) 5165 (7·1%)
Ethnicity*
Hispanic or Latino 3851 (5·3%) 3423 (4·7%)
Not Hispanic or Latino 50 010 (68·6%) 51 354 (70·5%)
Other 276 (0·4%) 123 (0·2%)
Unknown 18 723 (25·7%) 17 960 (24·7%)
Language*
English 59 518 (81·7%) 61 666 (84·6%)
Not available 12 203 (16·7%) 10 477 (14·4%)
Other 333 (0·5%) 256 (0·4%)
Spanish 806 (1·1%) 461 (0·6%)
Insurance*
Medicaid 2938 (4·0%) 9199 (12·6%)
Medicare 4487 (6·2%) 10 668 (14·6%)
Other 931 (1·3%) 712 (1·0%) 
Other (public) 428 (0·6%) 993 (1·4%)
Private 24 200 (33·2%) 7879 (10·8%)
Self-pay 2516 (3·5%) 3833 (5·3%)
Unknown 37 360 (51·3%) 39 576 (54·3%)
Data are n (%) or median (IQR). Unknown data include those files where the 
patient had declined to classify. FEP=first episode of psychosis. *p<0·0001, χ² test. 
†p<0·0001, Wilcoxon test. 
Table 1: Sociodemographic characteristics of the study population
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optimised to predict 1 year before diagnosis whether a 
FEP would occur. Importantly for potential prospective 
use in clinical routine, this learning process is dynamic 
because DETECT can update its prediction every time a 
new event enters the database. A detailed description of 
DETECT’s architecture, parameters, and design choices 
is provided in the appendix (pp 3–4).
DETECT was applied to the validation dataset to 
measure its prognostic performance: accuracy (true 
classifications divided by total classifications) and area 
Figure 3: Geographical distribution of individuals in FEP and control cohorts
(A) States with significant differences in distribution of individuals in the FEP and control cohorts (state-wise binomial tests, Bonferroni-corrected significance level 
of p=0·001). (B) Combined geographical distribution of 145 720 individuals included in this study across US states. The cutoff is at 54154 because this was the highest 
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under receiver operating characteristic curve (AUROC), 
in line with methodological guidelines.33 Since prognostic 
performance measures do not tell us whether DETECT 
would do more harm than good if used in clinical 
routine,38 we additionally estimated its potential clinical 
utility by doing decision-curve analyses.39 Decision-curve 
analyses relate the threshold probability of when an 
individual would be considered at sufficiently high risk 
to be detected to the cost of false positives (ie, detection 
when none is needed) and true positives. These quantities 
can then directly be related to the relative value (net 
benefit) of benefits (ie, detecting psychosis risk in EHR) 
and harms (unnecessary detection of psychosis risk in 
EHR) associated with a risk-prediction model. The net 
benefit values in the analysis are abstractions that simply 
rely on the assumption that benefits and harms are 
assessed using the same measurement units. In practice, 
benefits and harms could, for example, be assessed 
using quality-adjusted life-years, health-care costs, or a 
combination of such measures. The decision-curve 
analyses measured the net benefit of DETECT in two 
different scenarios. The first scenario considered the net 
benefit of a single-time prediction (eg, at a certain age for 
all individuals) for predicting risk for psychosis at any 
time in the future. The second scenario considered the 
net benefit of continuous-time assessment of individuals 
at any given time, to detect patients at high risk for 
developing a FEP that would lead to schizophrenia at a 
specific future point in time (eg, 1 year after assessment). 
This second scenario is more conservative since it has a 
more restricted target population and does not consider 
benefits of detecting individuals at risk who will develop 
schizophrenia in the longer term. To adjust for the under-
sampling of controls due to the case-control design,40 the 
calculations were adjusted by lifetime prevalence of non-
affective psychotic disorders in a general population (first 
scenario)41 and by point prevalence of schizophrenia 
(second scenario).42
To quantify DETECT’s prognostic performance on data 
from health-care providers that did not contribute data to 
the development dataset, the balanced accuracy (average 
of true positive and true negative classifications) and 
AUROC were further evaluated on the external test 
subset.
Role of the funding source
Lundbeck funded the study, but had no role in study 
design, data collection, and data interpretation. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
The FEP and control cohort each comprised 
72 860 individuals. 102 030 individuals (51 015 matching 
pairs) were randomly allocated to the development 
dataset and the remaining 43 690 to the validation dataset 
(figure 2). The median follow-up (observation time 
before index date) was 6·0 years (IQR 3·0–10·4). Because 
of the random splitting, there were no significant 
differences in follow-up between the development and 
validation datasets.
The development dataset consisted of data from 
encounters at 118 790 unique health-care providers. In the 
validation dataset, 4770 individuals (2287 in the FEP cohort 
and 2483 in the control cohort) had all their encounters 
outside of the 118 790 health-care providers that were 
encountered in the development dataset. The data from 
these individuals made up the external test subset 
Figure 4: Receiver operating characteristic curves
The curves show the prognostic performance of the recurrent neural network 
DETECT in the development and validation datasets and in the external 
validation subset. DETECT=Dynamic ElecTronic hEalth reCord deTection. 
FEP=first episode of psychosis.
















(prediction 1 year before FEP)
Validation dataset 
(prediction 1 year before FEP)
External validation subset dataset 
(prediction 1 year before FEP)
Figure 5: Distribution of DETECT’s predicted probabilities
Distribution of predicted risk probabilities of developing a FEP 1 year before the index date, by the recurrent neural 
network DETECT, for the FEP and control cohorts in the validation dataset. DETECT=Dynamic ElecTronic hEalth 
reCord deTection. FEP=first episode of psychosis.
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(figure 2). Median follow-up in the external test subset was 
4·1 years (IQR 2·1–8·3). 23 390 unique medical events 
were observed in the development dataset, and 4899 of 
these occurred in more than 50 patients and were thus 
included as predictors.43 There were significant differences 
(all p<0·0001) between the FEP and control cohorts with 
regards to sex, age, birth year, race and ethnicity, language, 
and insurance (table 1; appendix p 18). There were fewer 
women and white people, and more African Americans 
and English speakers in the FEP cohort compared with the 
control cohort. Also, compared with the control cohort, 
individuals in the FEP cohort were older, fewer had private 
health insurance, and a higher proportion was insured 
via Medicaid and Medicare (national health insurance 
programmes intended to help with medical costs for 
people with limited income and resources, older people, 
or people with disabilities). There were also regional 
differences in the distribution of individuals in the two 
cohorts (figure 3). Among the states with significant 
differences in distribution of individuals from the FEP and 
control cohort, Alaska stood out as having the largest over-
representation of individuals in the FEP cohort compared 
with individuals in the control cohort (approximately 5:1), 
and New Jersey, South Dakota, and Kansas stood out as 
having the largest under-representation of individuals in 
the FEP cohort compared with individuals in the control 
cohort (all approximately 1:5).
DETECT predicted whether a FEP would occur 1 year 
before the index date (figure 1) with an accuracy of 0·787 
and an AUROC of 0·868 in the development dataset. 
In the validation dataset, accuracy was 0·774 and AUROC 
was 0·856. In the external validation subset, balanced 
accuracy was 0·724 and AUROC was 0·799. The receiver 
operating characteristic curves are shown in figure 4. The 
distribution of predicted probabilities in the validation 
dataset is shown in figure 5. Decision-curve analysis in 
the validation dataset (figure 6) suggested that detection 
based on the predictions made by DETECT were 
potentially associated with a positive net benefit for cost-
benefit ratios below 1:3 in the first scenario (single-point 
risk assessment) and below 1:16 in the second scenario 
(continuous-time risk assessment). Analyses on the 
effect of follow-up time and number of observed events 
on prediction accuracy and sensitivity analyses are 
available in the appendix (p 5).
By measuring how DETECT changed its prediction 
with each new recorded event, the events associated with 
the largest positive and negative changes in predicted 
probability of FEP in the validation dataset were identified. 
The most common of these events (more than 
1000 occurrences in the validation dataset) are shown in 
tables 2 and 3. The top predictive events split on sex and 
age group are available in the appendix (pp 19–24). Across 
the top 100 events associated with the largest positive 
changes in predicted probability of FEP (appendix 
pp 25–27), approximately half were somatic or unspecified 
health-care encounters, while the remaining could be 
categorised as relating to psychiatric or brain health 
problems including substance dependence or abuse, or 
injury, assault, or self-harm. Illustrative examples of 
DETECT patient journeys showing the dynamic temporal 
pattern of recurrent neural network predictions for six 
individuals are shown in the appendix (pp 32–38).
Discussion
The main aim of the current study was to develop and 
validate an innovative risk-prediction model (DETECT) 
to detect individuals at risk of developing a FEP through 
EHRs that contain data from both primary and secondary 
care. DETECT showed adequate prognostic accuracy. 
Further replication and implementation research are 
needed to consolidate these findings.
Figure 6: Decision-curve analysis
Decision curve analysis in the validation dataset, showing the potential clinical usefulness of DETECT in two 
different scenarios. Shaded bands indicate 95% CIs of net benefit estimate. (A) Single-point risk assessment for 
FEP. Results are for a single-time use of DETECT (eg, at a certain age for all patients) to identify individuals at 
high risk for ever developing a FEP. To adjust for the oversampling of cases in the case-control design, this 
analysis is adjusted for a lifetime prevalence of non-affective psychotic disorders of 0·0229 in the general 
population.41 (B) Continuous-time risk assessment for FEP. Results are for use of DETECT to identify individuals 
at high risk for FEP in the immediate future. To adjust for the oversampling of cases, this analysis is adjusted for 
a point prevalence of schizophrenia of 0·0046.42 DETECT=Dynamic ElecTronic hEalth reCord deTection. FEP=first 
episode of psychosis.
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To achieve our primary aim, we employed one of the 
largest real-world EHR databases. To our knowledge, 
this is the largest EHR study (development dataset 
102 030 individuals; validation dataset 43 690 individuals; 
external test dataset 4770 individuals) covering approx-
imately 15% of the US population and encompassing both 
primary and secondary-care data. This represents a 
substantial advancement given that a recent review of 
91 risk-prediction modelling studies in this field found an 
average of 128 patients per study.44
DETECT was developed to reliably identify individuals 
potentially at risk of FEP 1 year in advance to ensure that 
risk prediction was done before the manifestation of more 
obvious behavioural pathology and functional morbidity. 
DETECT’s prognostic balanced accuracy and AUROC in 
the validation dataset (0·774 and 0·856) and in the external 
test subset (0·724 and 0·799) were adequate, on the basis 
of standard performance criteria.45 To be pragmatically 
useful, prognostic risk models must show above-chance 
performance in a population-based sample,46 and if 
implemented on a large scale, even risk-prediction models 
with a modest accuracy could be considered of clinical 
utility.47 If the results presented here are generalisable to a 
population-based setting, DETECT meets both of these 
targets, and therefore holds promise for clinical impact. 
To further explore the potential clinical utility of DETECT, 
prevalence-adjusted decision-curve analyses were done 
(figure 6) to illuminate the range of cost-benefit ratios for 
which use of DETECT was associated with net benefit in 
clinical use. Positive net benefits were seen for cost-benefit 
ratios below 1:3 in the single-point assessment and below 
1:16 in the continuous-time assessment. If these results 
can be replicated in an external population-based setting, 
DETECT could potentially be useful to screen EHRs on a 
large scale. The primary purpose of such large-scale 
screening would be to detect individuals at risk of FEP 
who might be missed by the current health-care pathways 
(such as the CHR-P specialised clinics). Because DETECT 
uses both primary care and secondary care data it might 
be possible to identify individuals at risk who do not 
actively seek help at secondary care or CHR-P clinics and 
whose psychiatric risk burden might not be identified in 
primary care. Such individuals are not accounted for in 
present detection strategies for individuals at risk, because 
there are no risk-prediction models developed for primary 
care.20 DETECT could be used in the context of a sequential 
and staged risk assessment framework to identify 
individuals at risk who might be referred to CHR-P clinics 
for additional face-to-face psychometric risk assessments 
and prognostic refinements.48
Another competitive advantage of DETECT is that it 
leverages recurrent neural network machine learning, a 
state-of-the-art deep learning method49 that can mitigate 
other methodological biases such as overfitting and 
prediction in the case of infrequent events.44 DETECT 
compares favourably to previous machine-learning 
models used to predict a FEP (or schizophrenia) from 
patient databases.50,51 A previous EHR study50 applied a 
stacked denoising autoencoder to data from about 
700 000 individuals to develop their so-called deep-patient 
representation. Using this representation, a random forest 
algorithm predicted future diagnoses of schiz ophrenia in a 





events in FEP 
cohort versus 
control cohort
Median change in 
predicted FEP probability
Overall At first 
occurrence
Procedure: sampling of cervix for 
Papanicolaou smear
2072 1·43 0·06 0·19
Procedure: differential white blood cell 
count
1060 14·36 0·02 0·17
Diagnosis: bipolar disorder 1777 17·51 0·03 0·15
Procedure: thin layer chromatography 
measurement
1083 9·72 0·05 0·11
Procedure: glucagon measurement 1226 4·55 0·02 0·11
Procedure: globulin measurement 1029 5·47 0·05 0·1
Diagnosis: seizure 1237 4·7 0·03 0·1
Procedure: valproic acid measurement 1865 27·26 0·01 0·1
Observation: normal mean blood pressure 2553 1·53 0·06 0·09
Procedure: alcohol measurement 2223 17·22 0·04 0·08
Observation: abnormally low chloride 
(moles/volume) in serum or plasma
2191 3·17 0·05 0·08
Diagnosis: depressive disorder 3959 2 0·05 0·07
Procedure: drug screening test 2452 6·96 0·02 0·06
Diagnosis: chronic pain 1010 2·46 0·05 0·06
Observation: abnormally low urea nitrogen 
(mass/volume) in serum or plasma
1583 2·69 0·05 0·06
Diagnosis: chronic obstructive lung disease 1356 2·27 0·04 0·06
Observation: normal ratio of haemoglobin 
A1c to total haemoglobin in blood
2084 1·2 0·05 0·06
Procedure: mental state finding 1178 3·53 0·02 0·05
Diagnosis: dental consultation and report 1081 3·11 0·02 0·05
Observation: normal ratio of nucleated 
erythrocytes per 100 leucocytes in blood
2700 2·73 0·03 0·05
Encounter: psychiatric visit 2755 9·8 0·01 0·05
Observation: normal potassium 
(moles/volume) in blood
3899 1·45 0·04 0·05
Procedure: subsequent hospital visits by 
physician 
2113 2·28 0·02 0·05
Observation: normal number of erythrocytes 
per volume in blood
28426 1·9 0·03 0·05
Diagnosis: long-term drug therapy 4954 1·71 0·04 0·05
Procedure: smoking cessation education 1563 0·96 0·04 0·05
Observation: normal oxygen saturation in 
arterial blood by pulse oximetry
4263 0·94 0·04 0·05
Observation: normal prothrombin time 1306 2·23 0·03 0·04
Diagnosis: tobacco dependence syndrome 6893 2·76 0·02 0·04
Procedure: urine pregnancy test by visual 
color comparison methods
3053 1·41 0·03 0·04
Top 30 events with largest positive change in predicted FEP probability after first occurrence (minimum 1000 occurrences 
of event in test dataset). FEP=first episode of psychosis. 
Table 2: Most predictive events in electronic health records with largest positive change
Articles
www.thelancet.com/digital-health   Vol 2   May 2020   e237
cut point) with an AUROC of 0·853 in a population-based 
internal test set (76 214 individuals). This result can largely 
be ascribed to the fact that the deep-patient representation 
included previous diagnoses of psychosis or schizophrenia 
and prescriptions of anti psychotic medications. DETECT 
had a substantially harder task since it aimed to predict a 
broader domain (FEP) and longer time before occurrence 
(365 days), without using diagnoses of previous psychoses 
or prescriptions of antipsychotic medication as predictors. 
Additionally, DETECT is innovative because it produces 
time-dynamic predictions that could better map the 
evolving phenomenological nature of emerging psychosis. 
At the same time, this feature of the model will allow 
DETECT to adapt better to future implementation in 
clinical routine, which is characterised by a dynamic 
collection of predictors. Among DETECT’s predictors, 
we found many known risk factors52 (table 2) and 
predictors that have associations with known risk factors 
(eg, hepatitis C and HIV infections from intravenous drug 
use, tests of kidney health because of lithium treatment, 
urinary incontinence as a side-effect of lithium or 
anticonvulsants). However, a substantial proportion of the 
most predictive events were not of a psychiatric nature (eg, 
sampling of cervix for Papanicolaou smear, differential 
white blood cell count). Although the small contributions 
of the majority of DETECT’s predictors might seem 
individually irrelevant, they have a cumulative prognostic 
value and empirically might be associated with a more 
intensive use of the health-care system for individuals at 
risk. The patient journey plots (appendix pp 32–38) 
exemplify how DETECT employs the predictors, updating 
its prediction at every event. The patient journey plots 
show whether a high predicted risk is based on a few 
high-impact events or on many events with smaller 
contributions, and could help interpret the clinical 
significance of DETECT’s predictions. This approach 
would mitigate the so-called black box nature of most 
machine-learning approaches, where the process behind 
predictions is opaque and eventual decisions relating to 
patient care are not fully transparent.53
This study has some limitations. First, both model 
development and validation were done in a case-control 
setting, and although minimal matching between case and 
control cohorts was done to ensure that the control cohort 
mimicked the characteristics of the full population (to 
improve the likelihood of generalisability of the results), 
the undersampling and matching of the control cohort 
might affect generalisability of the prediction results. 
Furthermore, the case-control setting might also have 
affected the validity of the prevalence adjustment done 
in the decision-curve analysis. Thus, population-based 
validation studies are needed before implementation can 
be considered. Another important limitation is that most 
individuals only have data covering a limited time window 
of their life, and data might be missing if they have used 
health-care providers outside of the network. Although 
EHR data represent data from real-world clinical practice 
with high ecological validity, they do not necessarily reflect 
research-based criteria. However, the use of structured 
diagnostic interviews can themselves lead to selection of 
patient subsamples and introduce additional bias.54 There 
is meta-analytical evidence indicating that for psychotic 





events in FEP 
cohort versus 
control cohort
Median change in 
predicted FEP probability
Overall At first 
occurrence
Procedure: cytopathology procedure, 
preparation of smear, genital source
2331 0·28 –0·04 –0·07
Procedure: prostate specific antigen 
measurement
2180 0·36 –0·04 –0·07
Prescription: thyroxine 1631 0·25 –0·03 –0·06
Diagnosis: atrial fibrillation 1007 0·71 –0·04 –0·06
Procedure: surgical pathology procedure 2952 0·46 –0·05 –0·06
Procedure: review of medication 17 144 0·31 –0·03 –0·06
Diagnosis: fever 1210 0·52 –0·05 –0·06
Procedure: child health procedures 1331 0·13 –0·02 –0·06
Observation: normal prostate specific 
antigen (mass/volume) in serum or plasma
1569 0·49 –0·04 –0·06
Observation: abnormally low number of 
lymphocytes per volume in blood 
1151 1·4 –0·05 –0·05
Prescription: atorvastatin 1387 0·4 –0·03 –0·05
Observation: normal bodyweight 
(percentile) per age
12 570 0·28 –0·02 –0·04
Diagnosis: otitis media 1435 0·35 –0·02 –0·04
Procedure: screening mammography 5204 0·3 –0·03 –0·04
Diagnosis: screening status 2467 0·31 –0·03 –0·04
Diagnosis: pre-surgery evaluation 1061 0·52 –0·03 –0·04
Prescription: metoprolol 1455 0·48 –0·03 –0·04
Procedure: Streptococcus pneumoniae 
group A antigen assay
1793 0·29 –0·02 –0·04
Procedure: comprehensive interview and 
evaluation
3999 0·18 –0·02 –0·04
Observation: abnormally low body-mass 
index (ratio)
6620 0·21 –0·01 –0·03
Procedure: weight and body-mass 
assessment procedure
1885 0·28 –0·02 –0·03
Observation: normal body-mass index 
(percentile)
9125 0·33 –0·02 –0·03
Diagnosis: coronary arteriosclerosis 1749 1·09 –0·02 –0·03
Prescription: amlodipine 1061 0·56 –0·02 –0·03
Prescription: lisinopril 2551 0·52 –0·02 –0·03
Prescription: amoxicillin 2097 0·29 –0·02 –0·03
Prescription: fentanyl 1906 0·42 –0·03 –0·03
Procedure: taking patient vital signs 
assessment
2064 0·21 –0·01 –0·03
Procedure: computer-assisted image 
analysis
1878 0·34 –0·02 –0·03
Procedure: haematology test 1564 2·65 –0·02 –0·03
Top 30 events with largest negative change in predicted FEP probability after first occurrence (minimum 1000 
occurrences of event in test dataset). FEP=first episode of psychosis.
Table 3: Most predictive events in electronic health records with largest negative change
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generally predictive of true diagnosis.55 Furthermore, the 
intended use of DETECT within a sequential assessment 
framework mitigates these issues. Another limitation of 
this study is that DETECT is specifically tuned to detect a 
FEP in patients that will then get diagnosed with 
schizophrenia, and it is not tuned to detect all non-affective 
psychoses. Additionally, the external validation subset of 
data from health-care providers that did not contribute 
data to the development dataset was used to establish if the 
prediction results could be generalised to individuals who 
did not have any encounter with health-care providers that 
contributed data to the model development. Although our 
analysis suggested that prediction results could indeed 
be generalised, the population studied does not define 
an easily interpretable population. Since our results are 
geographically bound to the USA, further external 
(eg, geographical) validation in an independent population-
based setting is needed. Crucially, the potential clinical 
utility of DETECT should be confirmed by pilot feasibility 
implementation studies that adopt a prospective real-world 
design. Implemen tation studies are scarce,11 but should 
address empirical aspects of using DETECT such as ethical 
issues relating to the use of machine-learning methods 
to screen EHRs. Although patients generally welcome 
knowing their risk for developing serious mental 
disorders,56 future participatory research with the 
involvement of patients (and when applicable, their carers) 
is required. Additional implementation research should 
also address the clinicians’ adherence to the use of 
DETECT. The subsequent step would be to complete 
randomised large-scale studies to fully evaluate early 
detection of FEP using DETECT, and measure whether 
this model provides a clinical benefit and improves the 
outcomes of schizophrenia.57–60
Overall, our study shows that it is feasible to apply 
machine learning to patient-level EHR data to produce 
personalised, dynamic, and real-time predictions of the 
risk of developing a FEP. The model developed, DETECT, 
has adequate prognostic accuracy and holds promise 
of clinical utility. Before DETECT can be considered 
for clinical implementation it must be subjected to 
population-based validation, and empirical implemen-
tation challenges that might be associated with its use in 
clinical practice must be addressed.
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